A Spotlight on Novel Coronavirus (COVID – 19) with Various Types of Strains
Life Sciences-Microbiology
DOI:
https://doi.org/10.22376/ijpbs/lpr.2022.12.5.L206-220Keywords:
COVID-19, SARS-CoV-2, B.1.1.7, B.1.351, B.1.1.529, Contagious, Genetic Diversification, Prophylactic Interventions, Life- Threatening Disease, VOCAbstract
Deadly COVID-19 viruses have raised a pandemic situation in the year 2019, causing serious and contagious respiratory infections in humans. SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) is the main causative agent for this disease outbreak. The pandemic created a critical impact on the global economy. The emergence of SARS-CoV-2 in late 2019 was followed by a period of relative evolutionary stasis that lasted about 11 months. Since, late 2020, SARS-CoV-2 evolution has been characterized by the emergence of sets of mutations. This resulted so far, in over 2.7 million deaths and near about 122 million infection cases. Most mutations in the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) genome are either deleterious and swiftly purged or relatively neutral. As far as the concern is the variants it impacts the virus characteristics, including antigenicity and transmissibility in response to the modification of the human immune profile. In recent days, COVID-19 affected cases are rapidly increasing and it became difficult to inhibit this virus as they are continuously mutated in the host cell forming various new strains like B.1.1.7, B.1.351, P.1, P.2, B.1.1.529, etc. These monitoring, surveillance of variation, and sequencing efforts within the SARS-CoV-2 genome enabled the rapid identification of the first some of Variants of Concern (VOCs) in late 2020, where genome changes became the most observable impact on virus biology and disease transmission. In this review article, we tried to focus and spot the light on the genetic diversification of various strains, their nature, similarities and dissimilarities, mechanism of action, and the prophylactic interventions which could prevent this life-threatening disease in the long run.
References
Sofi MS, Hamid A, Bhat SU. SARS-CoV-2: A critical review of its history, pathogenesis, transmission, diagnosis and treatment. Biosaf Heal. 2020. 2(4):217-224
Alanagreh L, Alzoughool F, Atoum M. The human coronavirus disease covid-19: Its origin, characteristics, and insights into potential drugs and its mechanisms. Pathogens. 2020. 9(5):1-11.
Hashim HO, Mohammed MK, Mousa MJ, Abdulameer HH, Alhassnawi ATS, Hassan SA, et al. Infection with Different Strains of SARS-CoV-2 in Patients with COVID-19. Arch Biol Sci. 2020;72(4):575–85.
Jha NK, Jeyaraman M, Rachamalla M, Ojha S, Dua K, Chellappan DK, et al. Current Understanding of Novel Coronavirus: Molecular Pathogenesis, Diagnosis, and Treatment Approaches. Immuno. 2021. 1(1):30–66.
Fehr AR, Perlman S. Coronaviruses: An Overview of Their Replication and Pathogenesis. Coronaviruses. 2015. 1282:1–23.
Global study identifies common vulnerabilities across SARS-CoV-2, SARS-CoV-1 and MERS coronaviruses - Project Topics. Available from: https://www.projecttopics.org/global-study-identifies-common-vulnerabilities-across-sars-cov-2-sars-cov-1-and-mers-coronaviruses.html
Hu T, Liu Y, Zhao M, Zhuang Q, Xu L, He Q. A comparison of COVID-19, SARS and MERS. PeerJ. 2020. 8:e9725.
Yang Y, Peng F, Wang R, Guan K, Jiang T, Xu G, et al. The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J Autoimmun. 2020. 109:102434.
Khan AH, Abutaleb A, Khan NA, El Din Mahmoud A, Khursheed A, Kumar M. Co-occurring indicator pathogens for SARS-CoV-2: A review with emphasis on exposure rates and treatment technologies. Case Stud Chem Environ Eng. 2021. 1; 4:100113.
Zhang Z, Zhang Y, Liu K, Li Y, Lu Q, Wang Q, et al. The molecular basis for SARS-CoV-2 binding to dog ACE2. Nat Commun. 2021. 12(1):1–10.
Kirtane AR, Verma M, Karandikar P, Furin J, Langer R, Traverso G. Nanotechnology approaches for global infectious diseases. Nat Nanotechnol 2021. 16(4):369–84.
Barker H, Parkkila S. Bioinformatic characterization of angiotensin-converting enzyme 2, the entry receptor for SARS-CoV-2. PLoS One. 2020. 15(10):e0240647.
Taka E, Yilmaz SZ, Golcuk et al. Critical Interactions Between the SARS-CoV-2 Spike Glycoprotein and the Human ACE2 Receptor. J Phys Chem B. 2021. 125(21):5537–48.
Saxena SK, Kumar S, Baxi P, Srivastava N, Puri B, Ratho RK. Chasing COVID-19 through SARS-CoV-2 spike glycoprotein. VirusDisease 2020. 31(4):399–407.
Spiga O, Bernini A, Ciutti A, Chiellini S, Menciassi N, Finetti F, et al. Molecular modelling of S1 and S2 subunits of SARS coronavirus spike glycoprotein. Biochem Biophys Res Commun. 2003. 310(1):78–83.
Beeckmans S, Van Driessche E. Scrutinizing Coronaviruses Using Publicly Available Bioinformatic Tools: The Viral Structural Proteins as a Case Study. Front Mol Biosci. 2021. 8:1–29.
Othman H, Bouslama Z, Brandenburg JT, da Rocha J, Hamdi Y, Ghedira K, et al. Interaction of the spike protein RBD from SARS-CoV-2 with ACE2: Similarity with SARS-CoV, hot-spot analysis and effect of the receptor polymorphism. Biochem Biophys Res Commun. 2020. 527(3):702–708.
Salleh MZ, Derrick JP, Deris ZZ. Structural Evaluation of the Spike Glycoprotein Variants on SARS-CoV-2 Transmission and Immune Evasion. Int J Mol Sci. 2021. 22(14) 1-21.
Spinello A, Saltalamacchia A, Magistrato A. Is the Rigidity of SARS-CoV-2 Spike Receptor-Binding Motif the Hallmark for Its Enhanced Infectivity? Insights from All-Atom Simulations. J Phys Chem Lett. 2020. 11(12):4785–90.
El-Aziz TMA, Stockand JD. Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status. Infect Genet Evol. 2020. 83:104327.
Adaptive Immune Response – Concepts of Biology – 1st Canadian Edition [Internet]. [cited 2021 Oct 28]. Available from: https://opentextbc.ca/biology/chapter/23-2-adaptive-immune-response/
Gioia M, Ciaccio C, Calligari P, De Simone G, Sbardella D, Tundo G, et al. Role of proteolytic enzymes in the COVID-19 infection and promising therapeutic approaches. Biochem Pharmacol. 2020. 182:114225.
Oliveira GLV de, Oliveira CNS, Pinzan CF, Salis LVV de, Cardoso CR de B. Microbiota Modulation of the Gut-Lung Axis in COVID-19. Front Immunol. 2021. 12:635471.
CELL DEATH – Dr Rajiv Desai [Internet]. [cited 2021 Oct 28]. Available from: https://drrajivdesaimd.com/2014/01/01/cell-death/
IDSA Guidelines on the Treatment and Management of Patients with COVID-19. Available from: https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/
Kamat S, Kumari M. Repurposing Chloroquine Against Multiple Diseases with Special Attention to SARS-CoV-2 and Associated Toxicity. Front Pharmacol. 2021. 12:1–18.
Ullah M, Wahab A, Saeed S, Khan SU, Ali H, Humayun S, et al. Coronavirus and its terrifying inning around the globe: The pharmaceutical cares at the main frontline. Chemosphere. 2021. 275:129968.
Diomede L, Baroni S, Luigi A De, Piotti A, Lucchetti J, Fracasso C, et al. Doxycycline Inhibition of a Pseudotyped Virus Transduction Does Not Translate to Inhibition of SARS-CoV-2 Infectivity. Viruses. 2021. 13(9):1745.
Murgolo N, Therien AG, Howell B, Klein D, Koeplinger K, Lieberman LA, et al. SARS-CoV-2 tropism, entry, replication, and propagation: Considerations for drug discovery and development. PLOS Pathog. 2021. 17(2):e1009225.
Majumder J, Minko T. Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19. AAPS J. 2021. 23(14):1–22.
Venkatasubbaiah M, Dwarakanadha Reddy P, Satyanarayana S V. Literature-based review of the drugs used for the treatment of COVID-19. Curr Med Res Pract. 2020. 10(3):100–9.
Sahebnasagh A, Avan R, Saghafi F, Mojtahedzadeh M, Sadremomtaz A, Arasteh O, et al. Pharmacological treatments of COVID-19. Pharmacol Reports. 2020. 72(6):1446–78.
Dexamethasone should be a standard drug in severe COVID-19 [Internet]. [cited 2021 Nov 1]. Available from: https://www.news-medical.net/news/20200803/Dexamethasone-should-be-a-standard-drug-in-severe-COVID-19.aspx
Brzezinski RY, Rabin N, Lewis N, Peled R, Kerpel A, Tsur AM, et al. Automated processing of thermal imaging to detect COVID-19. Sci Rep. 2021. 11(1):17489
Pham B, Thomas SM, Lillie E, Lee T, et al. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis. BMJ Open. 2019. 9(5):1–11.
Fernandez-Ruiz R, Paredes JL, Niewold TB. COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease. Transl Res. 2021. 232:13–36.
Silliman CC, Ambruso DR, Boshkov LK. Transfusion-related acute lung injury. Blood. 2005. 105(6):2266–73.
Coronavirus variants and mutations: The science explained - BBC News [Internet]. [cited 2021 Nov 1]. Available from: https://www.bbc.com/news/science-environment-55404988
FAQ - Veritas [Internet]. [cited 2021 Nov 1]. Available from: https://www.veritasint.com/faq/
Eminent MIT Scientists Defend Controversial SARS-CoV-2 Genome Integration Results [Internet]. [cited 2021 Nov 1]. Available from: https://www.genengnews.com/topics/translational-medicine/eminent-mit-scientists-defend-controversial-sars-cov-2-genome-integration-results/
What is genomic sequencing and how is it being used against Covid-19 in Australia? | Health | The Guardian [Internet]. [cited 2021 Nov 1]. Available from: https://www.theguardian.com/australia-news/2020/aug/18/what-is-genomic-sequencing-and-how-is-it-being-used-against-covid-19-in-australia
Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines — a new era in vaccinology. Nat Rev Drug Discov. 2018. 17(4):261–79.
Variants of SARS-CoV-2 [Internet]. [cited 2021 Nov 1]. Available from: https://wikimili.com/en/Variants_of_SARS-CoV-2
COVID-19 Weekly Epidemiological Update [Internet]. [cited 2021 Nov 1]. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20210316_weekly_epi_update_31.pdf?sfvrsn=c94717c2_9&download=true
Tsabouri S, Makis A, Kosmeri C, Siomou E. Risk Factors for Severity in Children with Coronavirus Disease 2019: A Comprehensive Literature Review. Pediatr Clin North Am. 2021. 68(1):321–38.
Top 3000 Best High-End Authoritative Up-To-Date Coronavirus (COVID-19) Advice, News & Resources: A-Z [Internet]. [cited 2021 Nov 1]. Available from: https://www.theinternationalman.com/coronavirus.php
Robson B. COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles’ heel conserved region to minimize probability of escape mutations and drug resistance. Comput Biol Med. 2020. 121:103749.
COVID research: a year of scientific milestones [Internet]. [cited 2021 Nov 1]. Available from: https://www.nature.com/articles/d41586-020-00502-w/
Early details emerge about the new U.K. coronavirus variant | Science News for Students [Internet]. [cited 2021 Nov 1]. Available from: https://www.sciencenewsforstudents.org/article/coronavirus-covid-19-uk-variant-pandemic-spread
Misconceptions about Seasonal Flu and Flu Vaccines | CDC [Internet]. [cited 2021 Nov 1]. Available from: https://www.cdc.gov/flu/prevent/misconceptions.htm
Latest Coronavirus updates [Internet]. [cited 2021 Nov 1]. Available from: https://www.somerset.gov.uk/coronavirus/latest-coronavirus-updates/
mRNA Vaccines May Pack More Persistent Punch Against COVID-19 Than Thought – NIH Director’s Blog [Internet]. [cited 2021 Nov 1]. Available from: https://directorsblog.nih.gov/2021/07/13/mrna-vaccines-could-pack-more-persistent-punch-against-covid-19-than-thought/
Yoo HM, Kim I-H, Kim S. Nucleic Acid Testing of SARS-CoV-2. Int J Mol Sci. 2021. 22(11):6150.
Katoh K, Misawa K, Kuma K, Kiyata T. MAFFT: A novel method for rapid multiple sequence alignment based on fast Fourier transform. Nucleic Acids Res. 2002. 30(14):3059-66
Jackson M, Marks L, May GHW, Wilson JB. The genetic basis of disease. Essays Biochem. 2018. 62(5):643–723.
First Italian case of rare new Covid variant detected in Naples [Internet]. [cited 2021 Nov 1]. Available from: https://www.thelocal.it/20210217/first-italian-case-of-rare-new-covid-variant-detected-in-naples/
Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021. 19(7):409–24.
Moore JP, Offit PA. SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants. JAMA. 2021. 325(9):821–2.
Winger A, Caspari T. The spike of concern—the novel variants of sars-cov-2. Viruses. 2021;13(6):1–15.
Mohammadi M, Shayestehpour M, Mirzaei H. The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines. Brazilian J Infect Dis. 2021 Jul 1;25(4):101606.
Mu Variant – Meaning, Origin, & Examples | Dictionary.com [Internet]. [cited 2021 Nov 3]. Available from: https://www.dictionary.com/e/tech-science/mu-variant/
Lasek-Nesselquist E, Lapierre P, Schneider E, George K St., Pata J. The localized rise of a B.1.526 SARS-CoV-2 variant containing an E484K mutation in New York State. medRxiv. 2021. 21251868.
Annavajhala MK, Mohri H, Wang P, Nair M, Zucker JE, Sheng Z, et al. Emergence and expansion of SARS-CoV-2 B.1.526 after identification in New York. Nature. 2021. 597(7878):703–8.
New Variants - Page 2 - Therapeutic Solutions International, Inc. [Internet]. [cited 2021 Nov 1]. Available from: https://board.therapeuticsolutionsint.com/viewtopic.php?t=429&start=10
Coronavirus India Highlights: 1.32 Lakh Fresh COVID-19 Cases in India, 3,207 Deaths In 24 Hours [Internet]. [cited 2021 Nov 1]. Available from: https://www.ndtv.com/india-news/coronavirus-india-live-updates-delhi-records-623-new-covid-19-cases-2454233
Mlcochova P, Kemp S, Dhar MS, Papa G, Meng B, Mishra S, et al. SARS-CoV-2 B.1.617.2 Delta variant replication, sensitivity to neutralising antibodies and vaccine breakthrough. bioRxiv. 2021. 443253.
Research Stories | India Science, Technology & Innovation [Internet]. [cited 2021 Nov 1]. Available from: https://www.indiascienceandtechnology.gov.in/listingpage/research-stories
Srivastava S, Banu S, Singh P, Sowpati DT, Mishra RK. SARS-CoV-2 genomics: An Indian perspective on sequencing viral variants. J Biosci. 2021. 46(22):1–14.
Explained | Delta Plus Variants and What Does INSACOG Say About Them [Internet]. [cited 2021 Nov 1]. Available from: https://www.moneycontrol.com/news/business/companies/explained-delta-plus-variants-and-what-does-insacog-say-about-them-7141941.html
New coronavirus variant under investigation in UK [Internet]. [cited 2021 Nov 2]. Available from: https://www.msn.com/en-gb/news/uknews/new-coronavirus-variant-under-investigation-in-uk/ar-BB1efbjx
Ramundo MS, Jesus JG De, Andrade PS, Coletti TM. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science. 2021. 372(6544):815–21.
How does a virus mutate? Why do mutations happen as South African, UK and Brazil Covid variants continue to spread | Edinburgh News [Internet]. [cited 2021 Nov 2]. Available from: https://www.edinburghnews.scotsman.com/health/coronavirus/how-does-virus-mutate-why-do-mutations-happen-south-african-uk-and-brazil-covid-variants-continue-spread-3076550
Shalash AO, Hussein WM, Skwarczynski M, Toth I. Key Considerations for the Development of Safe and Effective SARS-CoV-2 Subunit Vaccine: A Peptide-Based Vaccine Alternative. Adv Sci. 2021. 8(16):2100985.
Farasani A. Biochemical role of serum ferratin and d-dimer parameters in COVID 19 diagnosis. Saudi J Biol Sci. 2021. 1–5.
Callaway E. Heavily mutated Omicron variant puts scientists on alert. Nature. 2021 Dec 2;600(7887):21–21.
Thakur V, Kanta Ratho R. OMICRON (B.1.1.529): A new SARS-CoV-2 variant of concern mounting worldwide fear. J Med Virol. 2021 Dec 22. 34936120.
What makes the Omicron variant spread so easily? - Los Angeles Times [Internet]. [cited 2022 Jan 25]. Available from: https://www.latimes.com/science/story/2021-12-23/what-is-it-about-the-omicron-variant-that-makes-it-spread-so-easily
Science Brief: Omicron (B.1.1.529) Variant | CDC [Internet]. [cited 2022 Jan 25]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-omicron-variant.html
sars-cov-2 variants of concern and variants under investigation in england technical briefing 29 - Google Search [Internet]. [cited 2022 Jan 25]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1036501/Technical_Briefing_29_published_26_November_2021.pdf
Ji W, Wang W, Zhao X, Zai J, Li X. Cross-species transmission of the newly identified coronavirus 2019-nCoV. J Med Virol. 2020 Apr 1;92(4):433–40.
Doukky, R.; Mangla, A.; Ibrahim, Z.; Poulin, M.F.; Avery, E.; Collado, F.M.; Kaplan, J.; Powell, L.H. Impact of Physical Inactivity on Mortality in Patients with Heart Failure. Am. J. Cardiol. 2016, 117, 1135–1143.
COVID: What we know about the ‘deltacron’ variant - Frontline [Internet]. [cited 2022 Jan 25]. Available from: https://frontline.thehindu.com/science-and-technology/covid-what-we-know-about-the-deltacron-variant/article38232935.ece
Matta S, Rajpal S, Chopra KK, Arora VK. Covid-19 vaccines and new mutant strains impacting the pandemic. Indian J Tuberc. 2021;68(2):171.
SEGUIMIENTO DE VARIANTES DEL SARS-COV-2 [Internet]. [cited 2021 Nov 2]. Available from: https://www.biogeociencias.com/03_microorganismos_inmunologia/2021/20210531 Seguimiento de variantes del SARS-CoV-2.htm
COVID-19 Weekly Epidemiological Update [Internet]. [cited 2021 Nov 3]. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20210629_weekly_epi_update_46.pdf
Tracking SARS-CoV-2 variants [Internet]. [cited 2022 Jan 28]. Available from: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/
SARS-CoV-2 Variant Classifications and Definitions [Internet]. [cited 2022 Jan 28]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications.html#anchor_1632158885160
Hossain MK, Hassanzadeganroudsari M, Apostolopoulos V. The emergence of new strains of SARS-CoV-2. What does it mean for COVID-19 vaccines? Expert Rev Vaccines. 2021;20(6):635–8.
Vasireddy D, Vanaparthy R, Mohan G, Malayala SV, Atluri P. Review of COVID-19 Variants and COVID-19 Vaccine Efficacy: What the Clinician Should Know? J Clin Med Res. 2021;13(6):317–25.
Published
How to Cite
Issue
Section
Copyright (c) 2022 Souvik Biswas, Dipan Roy, Biplab Debnath, Arijit Das, Rajarshi Nath, Mrinmoy Nag, Poushali Boral, Poulomi Biswas, Debajit Dewan, Nabanita Pramanick, Utkalika Sarkar, Souvik Chattopadhyay, Soumya Datta
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
